Contact
  • Black Facebook Icon
  • Black Twitter Icon
  • Black Instagram Icon
  • Black LinkedIn Icon

Addiction Recovery Research Center

Fralin Biomedical Research Institute

2 Riverside Circle

Roanoke, VA  24016

​​

Phone: 540-315-0205

Email: iqrr@vtc.vt.edu

Media Inquiries:

John Pastor, FBRI Director of Communications

Phone: 540-526-2222

Email: jdpastor@vt.edu

Terms of Use

Please do not create multiple accounts on IQRR. If you have forgotten any of your information, you can email us. To see additional terms of use click here.

© 2019 by the Addiction Recovery Research Center. Proudly created with Wix.com

    NPR: FDA may block new addiction drug (6 min)

    May 24, 2019: This article from NPR describes how Sublocade, a long-acting, injectable form of buprenorphine that can help people in recovery from opioid addiction, was designated an “orphan drug” by the FDA for a non-traditional reason. This designation meant that it would have exclusive access to US markets for seven years (instead of the typical three), starting in 2017. However, a similar drug called Brixadi has been developed and is “ready for market,” but physicians may have to wait until 2024 for it to be available. You can read more about the drugs and the FDA here.